Neovasc Announces Partial Prepayment of Convertible Debenture
August 17, 2020 09:00 ET
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Aug. 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that Strul Medical Group LLC (“SMG”)...
Neovasc Announces US$12.6 Million Registered Direct Offering Priced At-the-Market
August 10, 2020 08:00 ET
|
Neovasc, Inc.
VANCOUVER, CANADA, Aug. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive...
PAVmed to Hold Business Update Conference Call on May 21, 2020
May 11, 2020 09:30 ET
|
PAVmed Inc.
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
Neovasc Announces Receipt of Nasdaq Extension to Satisfy Market Cap Rule
May 01, 2020 17:00 ET
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, May 01, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive...
PAVmed Subsidiary Lucid Diagnostics’ EsoCheck Esophageal Cell Collection Device Receives Prestigious Edison Best New Product Award
April 02, 2020 09:30 ET
|
PAVmed Inc.
NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVmed Receives $6.3 Million in Gross Proceeds from Completion of November 2019 Financing
March 31, 2020 09:30 ET
|
PAVmed Inc.
NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has...
PAVmed Announces FDA 510(k) Re-submission for its CarpX™ Minimally Invasive Carpal Tunnel Device
March 09, 2020 09:30 ET
|
PAVmed Inc.
Incorporates data from successful clinical safety study in which all patients met pre-specified safety and effectiveness endpoints NEW YORK, March 09, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq:...
PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients
March 02, 2020 09:30 ET
|
PAVmed Inc.
Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires multiple and...
Apos Medical Assets Ltd. Announces $11 Million Series A Extension Funding Round Led by Existing Shareholders
February 17, 2020 11:58 ET
|
AposTherapy
NEW YORK, Feb. 17, 2020 (GLOBE NEWSWIRE) -- Apos Medical Assets Ltd.—a global medical device company operating in the US, UK, Israel and Singapore—announced today that it has raised $11 million in a...
PAVmed Reports Second Quarter 2019 Financial Results and Provides Business Update
September 05, 2019 09:30 ET
|
PAVmed Inc.
Conference call to be held on September 5, 2019 at 4:30 p.m. Eastern time NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly...